Across TCGA pan-cancer cohorts, MIR6511A4 RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated MIR6511A4 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR6511A4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MIR6511A4 expression acts as an unfavorable survival marker.
STAD and KIRC are the cancer types where MIR6511A4 RNA most reproducibly stratifies survival.